Innovative use of intravesical tacrolimus for hemorrhagic radiation cystitis

Chirag N. Dave, Fahad Chaus, Michael B. Chancellor, Michelle Lajness, Kenneth M. Peters

Research output: Contribution to journalLetter

Abstract

Hemorrhagic cystitis is a rare and severe late complication of pelvic radiation, and there is no regulatory-approved drug treatment. We present an 81-year-old man with a history of localized prostate cancer, which was treated with external beam radiation therapy and subsequently developed severe hemorrhagic radiation cystitis for which he has failed several treatments. We present the novel use of intravesical tacrolimus for the treatment of refractory radiation cystitis and gross hematuria. The patient tolerated the treatment well, and it resulted in the resolution of his gross hematuria without further consideration for formalin instillation or cystectomy and diversion. Intravesical tacrolimus is a safe, minimally invasive, and promising treatment option for radiation hemorrhagic cystitis.

Original languageEnglish (US)
Pages (from-to)1679-1681
Number of pages3
JournalInternational urology and nephrology
Volume47
Issue number10
DOIs
StatePublished - Oct 1 2015

Keywords

  • Hemorrhagic cystitis
  • Prostate cancer
  • Radiation cystitis
  • Tacrolimus

ASJC Scopus subject areas

  • Nephrology
  • Urology

Fingerprint Dive into the research topics of 'Innovative use of intravesical tacrolimus for hemorrhagic radiation cystitis'. Together they form a unique fingerprint.

  • Cite this

    Dave, C. N., Chaus, F., Chancellor, M. B., Lajness, M., & Peters, K. M. (2015). Innovative use of intravesical tacrolimus for hemorrhagic radiation cystitis. International urology and nephrology, 47(10), 1679-1681. https://doi.org/10.1007/s11255-015-1098-6